1). Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation. 2004; 78:242–9.
Article
2). Morath C, Ritz E, Zeier M. Protocol biopsy: what is the rationale and what is the evidence? Nephrol Dial Transplant. 2003; 18:644–7.
Article
3). Moreso F, Ibernon M, Goma M, Carrera M, Fulladosa X, Hueso M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant. 2006; 6:747–52.
Article
4). Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003; 349:2326–33.
Article
5). Min SI, Yun IJ, Kang JM, Park YJ, Min SK, Ahn C, et al. Moderate-to-severe early-onset hyperuricaemia: a prognostic marker of longterm kidney transplant outcome. Nephrol Dial Transplant. 2009; 24:2584–90.
Article
6). Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999; 55:713–23.
Article
7). hoi BS, Shin MJ, Shin SJ, Kim YS, Choi YJ, Kim YS, et al. Clinical significance of an early protocol biopsy in living-donor renal transplantation: ten year experience at a single center. Am J Transplant. 2005; 5:1354–60.
8). Furness PN, Philpott CM, Chorbadjian MT, Nicholson ML, Bosmans JL, Corthouts BL, et al. Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. Transplantation. 2003; 76:969–73.
Article
9). Wilczek HE. Percutaneous needle biopsy of the renal allograft. A clinical safety evaluation of 1129 biopsies. Transplantation. 1990; 50:790–7.
10). Masin-Spasovska J, Spasovski G, Dzikova S, Petrusevska G, Lekovski Lj, Ivanovski N, et al. Do we have to treat subclinical rejections in early protocol renal allograft bi-opsies? Transplant Proc. 2007; 39:2550–3.
Article
11). Rush D, Nickerson P, Gough J, McKenna R, Grimm P, Cheang M, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol. 1998; 9:2129–34.
Article
12). Rush D. Protocol biopsies for renal transplantation. Saudi J Kidney Dis Transpl. 2010; 21:1–9.
13). Beimler J, Zeier M. Borderline rejection after renal transplantation – to treat or not to treat. Clin Transplant. 2009; 23(Suppl 21):19–25.
Article
14). Kee TY, Chapman JR, O'Connell PJ, Fung CL, Allen RD, Kable K, et al. Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants. Transplantation. 2006; 82:36–42.
Article
15). Rush D, Arlen D, Boucher A, Busque S, Cockfield SM, Girardin C, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant. 2007; 7:2538–45.
Article
16). Mao Y, Yu J, Chen J, Yang H, He Q, Shou Z, et al. Diagnosis of renal allograft subclinical rejection by urine protein fingerprint analysis. Transpl Immunol. 2008; 18:255–9.
Article